These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1089 related articles for article (PubMed ID: 32955174)

  • 1. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
    Hussain M; Mateo J; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Sartor O; Agarwal N; Olmos D; Thiery-Vuillemin A; Twardowski P; Roubaud G; Özgüroğlu M; Kang J; Burgents J; Gresty C; Corcoran C; Adelman CA; de Bono J;
    N Engl J Med; 2020 Dec; 383(24):2345-2357. PubMed ID: 32955174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    de Bono J; Mateo J; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Sartor O; Agarwal N; Olmos D; Thiery-Vuillemin A; Twardowski P; Mehra N; Goessl C; Kang J; Burgents J; Wu W; Kohlmann A; Adelman CA; Hussain M
    N Engl J Med; 2020 May; 382(22):2091-2102. PubMed ID: 32343890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
    Thiery-Vuillemin A; de Bono J; Hussain M; Roubaud G; Procopio G; Shore N; Fizazi K; Dos Anjos G; Gravis G; Joung JY; Matsubara N; Castellano D; Degboe A; Gresty C; Kang J; Allen A; Poehlein C; Saad F
    Lancet Oncol; 2022 Mar; 23(3):393-405. PubMed ID: 35157830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
    Saad F; Clarke NW; Oya M; Shore N; Procopio G; Guedes JD; Arslan C; Mehra N; Parnis F; Brown E; Schlürmann F; Joung JY; Sugimoto M; Sartor O; Liu YZ; Poehlein C; Barker L; Del Rosario PM; Armstrong AJ
    Lancet Oncol; 2023 Oct; 24(10):1094-1108. PubMed ID: 37714168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
    Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
    Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
    Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
    Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW
    Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
    Mateo J; Carreira S; Sandhu S; Miranda S; Mossop H; Perez-Lopez R; Nava Rodrigues D; Robinson D; Omlin A; Tunariu N; Boysen G; Porta N; Flohr P; Gillman A; Figueiredo I; Paulding C; Seed G; Jain S; Ralph C; Protheroe A; Hussain S; Jones R; Elliott T; McGovern U; Bianchini D; Goodall J; Zafeiriou Z; Williamson CT; Ferraldeschi R; Riisnaes R; Ebbs B; Fowler G; Roda D; Yuan W; Wu YM; Cao X; Brough R; Pemberton H; A'Hern R; Swain A; Kunju LP; Eeles R; Attard G; Lord CJ; Ashworth A; Rubin MA; Knudsen KE; Feng FY; Chinnaiyan AM; Hall E; de Bono JS
    N Engl J Med; 2015 Oct; 373(18):1697-708. PubMed ID: 26510020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance Olaparib for Germline
    Golan T; Hammel P; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Schlienger K; Locker GY; Kindler HL
    N Engl J Med; 2019 Jul; 381(4):317-327. PubMed ID: 31157963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis.
    Matsubara N; Nishimura K; Kawakami S; Joung JY; Uemura H; Goto T; Kwon TG; Sugimoto M; Kato M; Wang SS; Pang ST; Chen CH; Fujita T; Nii M; Shen L; Dujka M; Hussain M; de Bono J
    Jpn J Clin Oncol; 2022 May; 52(5):441-448. PubMed ID: 35229141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
    Mateo J; Porta N; Bianchini D; McGovern U; Elliott T; Jones R; Syndikus I; Ralph C; Jain S; Varughese M; Parikh O; Crabb S; Robinson A; McLaren D; Birtle A; Tanguay J; Miranda S; Figueiredo I; Seed G; Bertan C; Flohr P; Ebbs B; Rescigno P; Fowler G; Ferreira A; Riisnaes R; Pereira R; Curcean A; Chandler R; Clarke M; Gurel B; Crespo M; Nava Rodrigues D; Sandhu S; Espinasse A; Chatfield P; Tunariu N; Yuan W; Hall E; Carreira S; de Bono JS
    Lancet Oncol; 2020 Jan; 21(1):162-174. PubMed ID: 31806540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    Clarke NW; Armstrong AJ; Thiery-Vuillemin A; Oya M; Shore N; Loredo E; Procopio G; de Menezes J; Girotto G; Arslan C; Mehra N; Parnis F; Brown E; Schlürmann F; Joung JY; Sugimoto M; Virizuela JA; Emmenegger U; Navratil J; Buchschacher GL; Poehlein C; Harrington EA; Desai C; Kang J; Saad F
    NEJM Evid; 2022 Sep; 1(9):EVIDoa2200043. PubMed ID: 38319800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
    Robson M; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Delaloge S; Li W; Tung N; Armstrong A; Wu W; Goessl C; Runswick S; Conte P
    N Engl J Med; 2017 Aug; 377(6):523-533. PubMed ID: 28578601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.
    Matsubara N; de Bono J; Olmos D; Procopio G; Kawakami S; Ürün Y; van Alphen R; Flechon A; Carducci MA; Choi YD; Hotte SJ; Korbenfeld E; Kramer G; Agarwal N; Chi KN; Dearden S; Gresty C; Kang J; Poehlein C; Harrington EA; Hussain M
    Clin Cancer Res; 2023 Jan; 29(1):92-99. PubMed ID: 36318705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in
    Li Y; Lin S; Zhong L; Luo S; Huang X; Huang X; Dong L; Xu X; Weng X
    Pharmacogenomics; 2021 Aug; 22(13):809-819. PubMed ID: 34517749
    [No Abstract]   [Full Text] [Related]  

  • 16. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
    de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
    Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib.
    Stopsack KH
    Eur Urol; 2021 Apr; 79(4):442-445. PubMed ID: 33012578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant Olaparib for Patients with
    Tutt ANJ; Garber JE; Kaufman B; Viale G; Fumagalli D; Rastogi P; Gelber RD; de Azambuja E; Fielding A; Balmaña J; Domchek SM; Gelmon KA; Hollingsworth SJ; Korde LA; Linderholm B; Bandos H; Senkus E; Suga JM; Shao Z; Pippas AW; Nowecki Z; Huzarski T; Ganz PA; Lucas PC; Baker N; Loibl S; McConnell R; Piccart M; Schmutzler R; Steger GG; Costantino JP; Arahmani A; Wolmark N; McFadden E; Karantza V; Lakhani SR; Yothers G; Campbell C; Geyer CE;
    N Engl J Med; 2021 Jun; 384(25):2394-2405. PubMed ID: 34081848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
    Martin GA; Chen AH; Parikh K
    Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.